Collectively, these observations have hinted that atherosclerotic plaques from subjects with DM II are more prone to rupture because of increased inflammatory activity.
T he increasing prevalence and incidence of diabetes mellitus (DM) type II is a global health issue. Subjects with DM II have a several-fold increased risk of atherosclerotic plaque rupture leading to cardiovascular events such as myocardial infarction and stroke. 1, 2 The risk of developing a first myocardial infarction is 2-to 4-fold higher in subjects with DM II, which corresponds to the risk of a person without DM with a previous myocardial infarction. 2 Patients with DM also have a 2-to 4-fold increased risk of stroke and peripheral artery disease. 3, 4 Plaque rupture is responsible for ≈75% of all acute coronary events and ≈90% of all carotid plaques causing ischemic stroke. 5, 6 Atherosclerotic plaques prone to rupture (often referred to as vulnerable plaques) are characterized by a lipidrich necrotic core, a high inflammatory activity, loss of vascular smooth muscle cells (VSMCs), and a thin fibrous cap degraded by matrix metalloproteinases (MMPs). 7 Evidence from autopsy studies suggests that the most important cause of plaque rupture is inflammation in the fibrous cap leading to degradation of the fibrous tissue by macrophage-derived proteases such as MMPs. 8, 9 The mechanisms responsible for the increased cardiovascular risk in DM remain to be fully understood, but much attention has pointed to the possible role of inflammation. 10, 11 DM II is associated with chronic low-grade systemic inflammation as assessed by moderately elevated C-reactive protein. 12 Studies have shown that plaques from subjects with DM II have more inflammatory cells and a greater necrotic core.
MMPs, tissue inhibitors of MMPs (TIMPs), collagen, and elastin, we demonstrate in this study that no significant difference in these inflammatory markers was to be found comparing plaques from subjects with and without DM II. Instead, plaques obtained from subjects with DM II showed markedly reduced levels of stabilizing extracellular matrix (ECM) proteins and growth factors, suggesting that the high risk for a plaque rupture may be attributed to an impaired tissue repair rather than an enhanced inflammatory activity.
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Results

Clinical Characteristics of the Study Cohort
Sixty-three plaques were obtained from 63 subjects with DM II and 134 plaques were obtained from 131 subjects without DM. Subjects with DM II had higher body mass index and plasma triglycerides, whereas plasma low-density lipoprotein cholesterol levels were lower. Higher numbers of symptomatic plaques were observed in patients with DM II (Table 1) . No significant difference (P=0.5) was found comparing patients with DM II (15, 54 [SD 8, 3] days) and patients without DM II (14, 57 [SD 8, 4] days) regarding time between symptoms and operation. For data regarding impact of clinical characteristics and medical treatment, see the online-only Data Supplement.
Inflammatory Markers in Plaques From Patients With DM II and Patients Without DM
We did not observe any significant differences in the number of macrophages and VSMCs in tissue sections from plaques obtained from subjects with or without DM ( Figure 1 ; Table 2 ). Furthermore, we did not find any differences in lipid staining. Analysis of plaque extracts revealed no significant differences in the content of chemokines (fractalkine, regulated on activation normal T cell expressed and secreted [RANTES] , monocyte chemoattractant protein-1, and macrophage inflammatory protein-1β) or in proinflammatory cytokines (interleukin-6 [IL-6], tumor necrosis factor-α, and interferon-γ) between plaques obtained from subjects with or without DM II (Table 2) . Collectively, these findings demonstrate that the 63 plaques, both symptomatic and asymptomatic, obtained from patients with DM II included in the present study were not characterized by increased inflammation compared with plaques from control subjects.
ECM Proteins, Growth Factors, MMPs, and TIMPs in Plaques From Patients With DM II and Patients Without DM
As the balance between inflammation and the presence of VSMCs and stabilizing ECM proteins is important for plaque stability, we also investigated the ECM content in plaques from subjects with and without DM. Plaques obtained from subjects with DM II had markedly lower content of collagen and elastin. We also observed decreased levels of the VSMC growth factor platelet-derived growth factor (PDGF) in plaques from patients with DM II (Table 2 ). The lower connective tissue content of diabetic plaques was not associated with increased protein levels of MMPs or lower levels of TIMPs. However, diabetic plaques were found to have lower content of MMP-2, a protease known to promote smooth (Figure 2A ). The expression of MMP-2 was more restricted but showed the same general pattern ( Figure 2B ).
Inflammation and ECM Proteins in Symptomatic Plaques
Most acute cardiovascular events are caused by rupture of atherosclerotic plaques. 5, 6 Inflammation is known to play a key role in the processes leading to increased plaque vulnerability and rupture. [7] [8] [9] In agreement with this notion, symptomatic plaques from nondiabetic patients had more macrophages and higher content of RANTES, monocyte chemoattractant protein-1, macrophage inflammatory protein-1β, IL-6 and tumor necrosis factor-α compared with asymptomatic plaques from nondiabetic patients (Table 3) . Moreover, the levels of MMP-1, MMP-9, and TIMP-1 were found to be increased in symptomatic plaques from patients without DM. In contrast, we did not observe any increased macrophage staining, nor higher levels of chemokines, proinflammatory cytokines, or MMP levels in symptomatic compared with asymptomatic plaques from patients with DM II (Table 4) . Symptomatic plaques from patients with DM II had significantly reduced levels of collagen, MMP-2, and PDGF ( Figure 3 ) as well as decreased macrophage staining compared with symptomatic plaques from patients without DM (P<0.05) and lower levels of inflammatory cytokine RANTES (P<0.05; Table 5 ). PDGF and collagen were significantly lower in asymptomatic plaques from patients with DM II compared with plaques obtained from patients without DM (Table 6 ).
These results show that symptomatic plaques from patients without DM are characterized by traditional markers of All parameters except histology are normalized against wet weight of the plaque. Comparisons were done using Mann-Whitney test for non-normally distributed variables and Student t test for normally distributed variables. Nonnormally distributed variables are presented as median (interquartile range) and normally distributed variables are presented as mean (±SD). IFN-γ indicates interferon-γ; IL-6, interleukin-6; MCP-1, monocyte chemoattractant protein-1; MIP-1β, macrophage inflammatory protein-1β; MMP, matrix metalloproteinase; NS, nonsignificant; PDGF, platelet-derived growth factor; RANTES, regulated on activation normal T cell expressed and secreted; TIMP, tissue inhibitors of matrix metalloproteinase; TNF-α, tumor necrosis factor-α; and VSMC, vascular smooth muscle cell. plaque vulnerability such as increased inflammation and matrix-degrading proteases compared with asymptomatic plaques, whereas symptomatic plaques obtained from patients with DM II did not show an increase of inflammatory cells, inflammatory activity, or increased levels of proteases. These findings suggest the involvement of driving forces other than inflammation on plaque vulnerability in patients with DM II.
Differences in DM II Plaque Composition Using Multivariate Analysis
To investigate possible differences in plaque characteristics in a multivariate analysis, principal component analysis was used. Principal component analysis is an unsupervised method and a data reduction technique that allows the major sources of variation in a multidimensional data set to be analyzed without introducing inherent bias. The principal component analysis model included the measured plaque characteristics listed in Tables 2 to 6 and the qualitative variables symptoms and DM II. The loadings scatter plot of the 2 first principal components of the model (Figure 4) shows that the plaque characteristics identified by univariate analysis in dichotomized groups as associated to DM II and symptoms are also clearly associated predominantly to either DM II or symptoms. The multivariate analysis confirms that plaques from nondiabetics were associated with markers of repair, in contrast to plaques from diabetics, and not markers of inflammation, which instead were associated with symptomatic plaques. To confirm the findings in the multivariate principal component All variables except histology are normalized against wet weight of the plaque. Comparisons were done using Mann-Whitney test for non-normally distributed variables and Student t test for normally distributed variables. Nonnormally distributed variables presented as median (interquartile range) and normally distributed variables are presented as mean (±SD). IFN-γ indicates interferon-γ; IL-6, interleukin-6; MCP-1, monocyte chemoattractant protein-1; MIP-1β, macrophage inflammatory protein-1β; MMP, matrix metalloproteinase; PDGF, platelet-derived growth factor; RANTES, regulated on activation normal T cell expressed and secreted; TIMP, tissue inhibitors of matrix metalloproteinase; TNF-α, tumor necrosis factor-α; and VSMC, vascular smooth muscle cell. *P<0.005; †P<0.01; ‡P<0.05. All variables except histology are normalized against wet weight of the plaque. Comparisons were done using Mann-Whitney test for non-normally distributed variables and Student t test for normally distributed variables. Nonnormally distributed variables presented as median (interquartile range) and normally distributed variables are presented as mean (±SD). IFN-γ indicates interferon-γ; IL-6, interleukin-6; MCP-1, monocyte chemoattractant protein-1; MIP-1β, macrophage inflammatory protein-1β; MMP, matrix metalloproteinase; PDGF, platelet-derived growth factor; RANTES, regulated on activation normal T cell expressed and secreted; TIMP, tissue inhibitors of matrix metalloproteinase; TNF-α, tumor necrosis factor-α; and VSMC, vascular smooth muscle cell.
analysis, we also analyzed general linear models for plaque characteristics versus the factors, symptoms, and DM II ( Table  I in the online-only Data Supplement). This analysis revealed that macrophages, lipids, macrophage inflammatory protein-1β, IL-6, MMP-1, MMP-9, and TIMP-1 were associated with symptoms independently of DM II, whereas collagen, elastin, PDGF, MMP-2, and fractalkine were associated with DM II independently of symptoms.
Discussion
Currently, novel quantitative techniques for biological components such as Luminex are available, allowing us to study atherosclerosis beyond the histological approach. We have now used these new techniques to evaluate components important for plaque vulnerability, such as inflammation and ECM proteins, aiming to explore the composition of plaques from subjects with DM II, a well-known risk group for cardiovascular events. We found that differences in stabilizing plaque components and tissue repair seem to be the driving force of plaque vulnerability, rather than the inflammatory activity (now quantified in almost the whole plaque sample) in subjects with DM II.
Although markers of inflammation were significantly increased in symptomatic compared with asymptomatic plaques obtained from subjects without DM II, no such differences could be observed in subjects with DM II. Instead, our findings point to a reduced fibrous repair capacity, which could explain the increased plaque vulnerability in subjects with DM II. Plaques from subjects with DM II were characterized by markedly reduced levels of collagen and elastin, connective tissue proteins that are critical in maintaining the stability of atherosclerotic plaques. 7, 8 Moreover, plaques from subjects with DM II had significantly lower levels of PDGF and MMP-2, proteins that are involved in the activation of fibrous repair responses. [14] [15] [16] [17] [18] These findings suggest that plaques in subjects with DM II have an increased risk of becoming symptomatic not because of increased inflammation but rather because they have impaired fibrous repair capacity. This notion is also in line with other reports demonstrating decreased wound-healing capacity in subjects with DM. 19 The molecular mechanisms underlying the decreased content of collagen and elastin in plaques from patients with DM II remain to be fully characterized. The observational design of the present study does not allow conclusions regarding causality, but some interesting associations are noteworthy. PDGF and MMP-2 demonstrated significant associations with the plaque content of both collagen and elastin, and both PDGF and MMP-2 were decreased in plaques from patients with DM II. These associations were found using both dichotomic analyses and multivariate models. PDGF is a growth factor that stimulates VSMC proliferation and synthesis of ECM proteins. 15, 17 VSMCs are the principal connective tissue producing cells in atherosclerotic plaques and are important for maintaining plaque stability. 20 Inhibition of PDGF has been shown to delay fibrous cap formation in hypercholesterolemic mice. 21 MMP-2 is a gelatinase, which degrades collagen IV, a key regulatory step in the conversion of VSMCs into the synthetic, proliferative repair phenotype that is required for the induction of intimal repair responses.
14 MMP-2 also stimulates collagen synthesis. 16 In agreement with our findings, high MMP-2 levels are found in atherosclerotic plaques with the fibrous plaque phenotype. 18 Although this study was not designed to decipher mechanistic interactions, stainings for MMP-2 and PDGF revealed that both these factors colocalized with VSMCs. Collectively, these findings suggest that MMP-2 and PDGF act in concert to promote repair responses in plaque tissue and that this process is impaired in DM.
The association between DM and impaired tissue repair is well established. 19 Clinically, this is often seen as delayed wound healing and presence of chronic skin ulcers. The mechanisms responsible for delayed wound healing in DM have been extensively studied, and it is interesting to compare how these findings parallel the impaired fibrous repair in diabetic atherosclerotic plaques identified in this study.
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Figure 3. Decreased levels of tissue repair cytokines, collagen, and matrix metalloproteinase-2 (MMP-2) in symptomatic plaques from patients with type II diabetes mellitus compared with patients without diabetes mellitus. The levels of platelet-derived growth factor (PDGF; ng/g wet weight plaque; A), collagen (mg/g plaque wet weight; B), and MMP-2 (ng/g wet weight plaque; C). 22 PDGF has been shown to promote wound healing, and recombinant PDGF has been approved for treatment of chronic skin ulcers in DM. 23 Accordingly, it seems that decreased capacity to express PDGF is a common characteristic for the impaired repair response in DM, both in the skin and in the atherosclerotic plaques. 19 Previous studies comparing atherosclerotic plaques from diabetic and nondiabetic subjects have consistently shown increased inflammation in diabetic plaques. 1, 13, 24 However, these observations could not be confirmed in the more recent Oxford Plaque Study, which showed no difference in inflammatory cells between plaques from subjects with DM II and subjects with normal glucose tolerance. 25 In line with this study, we found no difference in inflammatory markers and macrophage staining between DM II and nondiabetic plaques in the present study. It is possible that these inconsistencies reflect differences in study design, cohorts, or analytic approach. An alternative explanation is that the different findings reflect changes in therapeutic standards. During the past 10 years, several randomized clinical trials have demonstrated the effectiveness of statins in primary prevention of cardiovascular disease in DM. 26 As a result of these observations, most subjects with DM II today are treated with statins. Accordingly, >90% of patients with DM in this study were All variables except histology are normalized against wet weight of the plaque. Comparisons were done using Mann-Whitney test for non-normally distributed variables and Student t test for normally distributed variables. Non-normally distributed variables presented as median (interquartile range) and normally distributed variables are presented as mean (±SD). IFN-γ indicates interferon-γ; IL-6, interleukin-6; MCP-1, monocyte chemoattractant protein-1; MIP-1β, macrophage inflammatory protein-1β; MMP, matrix metalloproteinase; PDGF, platelet-derived growth factor; RANTES, regulated on activation normal T cell expressed and secreted; TIMP, tissue inhibitors of matrix metalloproteinase; TNF-α, tumor necrosis factor-α; and VSMC, vascular smooth muscle cell. *P<0.05. All variables except histology are normalized against wet weight of the plaque. Comparisons were done using Mann-Whitney test for non-normally distributed variables and Student t test for normally distributed variables. Non-normally distributed variables presented as median (interquartile range) and normally distributed variables are presented as mean (±SD). IFN-γ indicates interferon-γ; IL-6, interleukin-6; MCP-1, monocyte chemoattractant protein-1; MIP-1β, macrophage inflammatory protein-1β; MMP, matrix metalloproteinase; PDGF, platelet-derived growth factor; RANTES, regulated on activation normal T cell expressed and secreted; TIMP, tissue inhibitors of matrix metalloproteinase; TNF-α, tumor necrosis factor-α; and VSMC, vascular smooth muscle cell. *P<0.05; †P<0.005.
on statin treatment. Most of the previous studies of inflammation in diabetic plaques have been done on samples collected before the publication of the landmark Collaborative Atorvastatin Diabetes Study (CARDS) in 2004 first demonstrating primary prevention of cardiovascular events in subjects with DM. 27 Although these publications do not provide information regarding the frequency of statin treatment in the study cohorts, it is likely to have been much lower than in the current study. It has been shown that treatment with statins markedly reduces the inflammatory activity in atherosclerotic plaques. 28 According to this study, inflammation does not seem to be upregulated in plaques obtained from patients with DM II, which might reflect the currently more widespread use of statins in patients with DM II.
The current notion in the field supports that plaque ruptures occur as a result of inflammation in thin parts of the fibrous cap involving degradation of collagen and elastin by MMPs released from activated macrophages. Our observation of increased macrophage accumulation and levels of RANTES, monocyte chemoattractant protein-1, macrophage inflammatory protein-1β, IL-6, tumor necrosis factor-α, MMP-1 and MMP-9 in symptomatic plaques from patients without DM II is in agreement with this notion. Although trends toward increased inflammation were also observed in symptomatic compared with asymptomatic plaques from subjects with DM II, this difference did not reach statistical significance. The lack of significant difference in inflammatory activation between symptomatic and asymptomatic plaques from subjects with DM II could be partly explained by insufficient statistical power because the number of plaques from subjects with DM II included in this study was lower than the number of plaques from subjects without DM II. However, it is also possible that an impaired fibrous repair response in plaques from subjects with DM II makes these lesions more susceptible to inflammatory destabilization and that rupture can occur already at a more modest state of inflammation.
The present study has certain limitations. It is unclear how representative advanced carotid lesions are for atherosclerotic lesions at other sites and at less advanced stages. The carotid surgery is commonly performed a few weeks after the acute event (mean time to surgery was 15.1 days in this study). Thereby it cannot be excluded that the biological characteristics of the removed plaque reflect an ongoing repair process rather than mechanisms involved in the development of plaque vulnerability. It is also possible that other inflammatory factors that were not measured in this study are involved in the inflammatory process in diabetic atherosclerotic plaques. Yet, an increase of other factors inducing an inflammatory response would most likely be reflected by general markers of inflammation such as tumor necrosis factor-α and IL-6. It could also be argued that the time from the clinical event to carotid surgery could affect our result considering the high percentage of symptomatic plaques in the group of patients with DM II. 29 However, as the plaques that were considered symptomatic had to be associated with symptoms in less than a month, this should not have a major influence on the present findings. Regarding the assessment of plaque inflammation based on histological analyses of tissue sections, this needs to be interpreted with due caution because they reflect only a minor part of the lesion and may not be representative of the lesion at large.
In conclusion, these observations provide insights into atherosclerosis in the particularly high-risk group of DM II. Plaques from subjects with DM II have reduced content of fibrous connective tissue proteins required to maintain plaque stability, as well as lower levels of factors known to promote the formation of fibrous tissue such as PDGF and MMP-2. This could make diabetic plaques more prone to rupture, requiring a significantly lower level of inflammatory activation for these plaques to cause symptoms. Multivariate principal component analysis (PCA) reveals that plaques from nondiabetics were associated with markers of repair, in contrast to plaques from diabetics, and not markers of inflammation, which instead were associated with symptomatic plaques. A loading scatter plot of the 2 first principal components is shown. The PCA model included measured plaque characteristics listed in Tables 2 to 6 and the qualitative variables symptoms and diabetes mellitus. The model included 3 principal components that explained 44% and could predict 11% of the variability (R 2 =0.44; Q 2 =0.11). Blue variables were found to be associated with diabetes mellitus and red variables with symptoms in univariate analyses (Tables 2 and 3) , whereas grey variables showed no univariate associations with diabetes mellitus or symptoms. IFN-γ indicates interferon-γ; IL-6, interleukin-6; MCP-1, monocyte chemoattractant protein-1; MIP-1β, macrophage inflammatory protein-1β; MMP, matrix metalloproteinase; PDGF, platelet-derived growth factor; RANTES, regulated on activation normal T cell expressed and secreted; TIMP, tissue inhibitors of matrix metalloproteinase; TNF-α, tumor necrosis factor-α; and VSMC, vascular smooth muscle cell.
The prevalence and incidence of diabetes mellitus is a rapidly increasing all over the world. Subjects with diabetes mellitus have several-fold increased risk of developing myocardial infarction and stroke. An enhanced inflammatory activity within the atherosclerotic plaque has been suggested as the driving force of plaque vulnerability in diabetes mellitus, but the exact cause remains unknown. In the present study, we show that human atherosclerotic carotid plaques obtained from patients with diabetes mellitus type II express markedly reduced levels of extracellular matrix proteins, collagen, and elastin important for plaque stability, as well as factors important for tissue repair. No tendency to an enhanced inflammatory activity was found. These findings suggest that an impaired tissue repair rather than an enhanced inflammatory activity may be the main cause of the high risk for plaque rupture in patients with diabetes mellitus type II.
Significance
